Stress and antibody response to vaccination: implications of animal studies for human clinical research.

Abstract:

:Psychological stress has been shown to be associated with poorer antibody levels following vaccination in both animals and humans, although the mechanisms underlying this relationship remain unclear. However, animal research has enabled investigation of how this relationship may be affected by the influence of individual differences in physiological and behavioral stress responses, the role of the timing of stress exposure and precise neuroendocrine and immunological mechanisms. By using these findings to inform future human research, we will be better able to achieve our goal of fully understanding and ultimately ameliorating, the effect of stress on antibody response to vaccination.

journal_name

Expert Rev Vaccines

authors

Burns V

doi

10.1586/14760584.3.2.141

keywords:

subject

Has Abstract

pub_date

2004-04-01 00:00:00

pages

141-9

issue

2

eissn

1476-0584

issn

1744-8395

pii

ERV030206

journal_volume

3

pub_type

杂志文章,评审
  • Effect of HIV exposure and timing of antiretroviral therapy initiation on immune memory responses to diphtheria, tetanus, whole cell pertussis and hepatitis B vaccines.

    abstract:OBJECTIVES:We evaluated memory responses and antibody persistence to diphtheria-toxoid, tetanus-toxoid, whole-cell-pertussis (DTwP), and Hepatitis-B vaccines in HIV-unexposed, HIV-exposed-uninfected and HIV-infected children previously randomized to initiate time-limited ART at 6-10 weeks (ART-Immed) or when clinically...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/14760584.2019.1547195

    authors: Simani OE,Izu A,Nunes MC,Violari A,Cotton MF,Van Niekerk N,Adrian PV,Madhi SA

    更新日期:2019-01-01 00:00:00

  • New challenges in therapeutic vaccines against HIV infection.

    abstract:INTRODUCTION:There is a growing interest in developing curative strategies for HIV infection. Therapeutic vaccines are one of the most promising approaches. We will review the current knowledge and the new challenges in this research field. Areas covered: PubMed and ClinicalTrial.gov databases were searched to review t...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2017.1322513

    authors: Leal L,Lucero C,Gatell JM,Gallart T,Plana M,García F

    更新日期:2017-06-01 00:00:00

  • Vaccines for lyssaviruses other than rabies.

    abstract::Several new lyssaviruses have emerged in the past decade and it is likely that more remain to be discovered. There are six recognized genotypes of lyssavirus other than the rabies virus (genotype 1). All but one of these has been associated with human cases, with the resulting disease clinically similar to rabies. Rab...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.4.4.533

    authors: Nel LH

    更新日期:2005-08-01 00:00:00

  • Effectiveness, immunogenicity and safety of one vs. two-dose varicella vaccination:a meta-analysis.

    abstract:BACKGROUND:Despite high 1-dose vaccination coverage, breakthrough varicella infections still occur. Therefore, 2-dose vaccination is recommended to enhance the immune response to the virus. However, the reported incremental vaccine effectiveness (VE) of 2-dose vaccination varies widely among studies. METHODS:To determ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/14760584.2018.1433999

    authors: Yin M,Xu X,Liang Y,Ni J

    更新日期:2018-04-01 00:00:00

  • Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors.

    abstract::Recombinant adenoviruses have emerged as promising viral vectors for CD8(+) T-cell vaccines. Our studies have indicated that unlike most acute infections, the CD8(+) T-cell memory population elicited by recombinant human adenovirus serotype 5 (rHuAd5) displays a dominant effector memory phenotype. Persistent, low-leve...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.88

    authors: Bassett JD,Swift SL,Bramson JL

    更新日期:2011-09-01 00:00:00

  • The RTS,S vaccine candidate for malaria.

    abstract::Malaria continues to be a worldwide leading cause of morbidity and mortality, and the development of an effective malaria vaccine remains a research imperative. Of the multiple approaches that have been pursued, the RTS,S/AS01 vaccine candidate represents the most developed and clinically validated malaria vaccine for...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.57

    authors: Regules JA,Cummings JF,Ockenhouse CF

    更新日期:2011-05-01 00:00:00

  • Protein/peptide and DNA vaccine delivery by targeting C-type lectin receptors.

    abstract::C-type lectin receptors (CLRs) are a class of pathogen-recognition receptors that are actively investigated in the field of vaccine delivery. Many of their properties have functions linked to the immune system. These receptors are expressed abundantly on antigen-presenting cells and are considered to be the sentinels ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.7.7.1005

    authors: Tang CK,Sheng KC,Apostolopoulos V,Pietersz GA

    更新日期:2008-09-01 00:00:00

  • SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier.

    abstract::The authors have purified a major capsid protein, VP1 of Simian virus 40 (SV40), using recombinant baculovirus and have established the method of in vitro reassembly of SV40 virus-like particles (SV40-VLPs) from VP1-pentamers. In this reassembly, SV40-VLPs can encapsulate approximately 5 kb exogenous DNA shielded by h...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.12.149

    authors: Kawano M,Matsui M,Handa H

    更新日期:2013-02-01 00:00:00

  • Alternative administration routes and delivery technologies for polio vaccines.

    abstract::Global polio eradication is closer than ever. Replacement of the live attenuated oral poliovirus vaccine (OPV) by inactivated poliovirus vaccine (IPV) is recommended to achieve complete eradication. Limited global production capacity and relatively high IPV costs compared to OPV spur the need for improved polio vaccin...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2016.1158650

    authors: Kraan H,van der Stel W,Kersten G,Amorij JP

    更新日期:2016-08-01 00:00:00

  • FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.

    abstract::The Leishmania donovani glycoprotein fraction, known as FML, successfully underwent preclinical and clinical (Phase I-III) vaccine trials against canine visceral leishmaniasis (92-95% of protection and 76-80% of vaccine efficacy) when formulated with a QS21 saponin-containing adjuvant. It became the licensed Leishmune...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1586/14760584.7.6.833

    authors: Palatnik-de-Sousa CB,Barbosa Ade F,Oliveira SM,Nico D,Bernardo RR,Santos WR,Rodrigues MM,Soares I,Borja-Cabrera GP

    更新日期:2008-08-01 00:00:00

  • Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma.

    abstract::There is growing interest in immunotherapy for malignant gliomas. This interest stems from a number of immunological observations, together with the failure of conventional therapeutic agents to produce broad and clinically meaningful improvements in survival and quality of life. The challenges faced in translating la...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2014.881255

    authors: Fenstermaker RA,Ciesielski MJ

    更新日期:2014-03-01 00:00:00

  • Vaccination and healthy aging.

    abstract::The aging process in humans is associated with a decrease in immune function (immunosenescence) and an increase in comorbid disorders. When combined with environmental factors this can lead to an increased risk and severity of infectious diseases. Diseases in older adults (>/=70 years) tend to be more severe and have ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.26

    authors: Maggi S

    更新日期:2010-03-01 00:00:00

  • Phagocytosis of synthetic particulate vaccine delivery systems to program dendritic cells.

    abstract::Therapeutic prospects of particulates are increasingly recognized for vaccination purposes. Compared with biologic particulates, such as live or attenuated bacterial vectors and viral vectors, synthetic particulates may be expected to ease the hurdles of quality assurance and validation in vaccine development and prod...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.1.2.215

    authors: Thiele L,Merkle HP,Walter E

    更新日期:2002-08-01 00:00:00

  • CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine.

    abstract::Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs act as immune adjuvants, improving the immune response elicited by coadministered vaccines. Combining CpG ODN with anthrax vaccine adsorbed (AVA), the licensed human vaccine, can increase the speed, magnitude and avidity of the resultant anti-ant...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.5.3.365

    authors: Klinman DM

    更新日期:2006-06-01 00:00:00

  • Protecting the most vulnerable age group: a review of MenACWY-TT immunogenicity and safety in infants.

    abstract:INTRODUCTION:Neisseria meningitidis causes invasive meningococcal disease (IMD), with the highest incidence observed in infants and young children. Meningococcal serogroups A, B, C, W, X, and Y account for almost all IMD cases worldwide. Available meningococcal vaccines targeting serogroups A, C, W, and Y (MenACWY) inc...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1080/14760584.2020.1745070

    authors: Martinón-Torres F,Serra L,Safadi MAP

    更新日期:2020-04-01 00:00:00

  • Host immunity to Bacillus anthracis lethal factor and other immunogens: implications for vaccine design.

    abstract::Infections of humans with Bacillus anthracis are an issue with respect to the biothreat both to civilians and military personnel, infections of individuals by infected livestock in endemic regions and, recently, infections of intravenous drug users injecting anthrax-contaminated heroin. Existing vaccination regimens a...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.981533

    authors: Altmann DM

    更新日期:2015-03-01 00:00:00

  • Vaccines: facing complex problems with the promise of immunology.

    abstract::Highly renowned in the vaccines world, Stanley A. Plotkin has worked at many leading institutions throughout his career, and is Emeritus Professor of the University of Pennsylvania and Adjunct Professor of the Johns Hopkins University. In 1991, Plotkin joined Sanofi Pasteur and worked there from 1991 to 1997, and now ...

    journal_title:Expert review of vaccines

    pub_type: 面试

    doi:10.1586/14760584.2014.934678

    authors: Plotkin SA,Rees J

    更新日期:2014-08-01 00:00:00

  • Do new TB vaccines have a place in the Expanded Program on Immunization?

    abstract::Several new TB vaccines are currently undergoing clinical trials. Among the most promising is a vaccine based upon the modified vaccinia virus Ankara-expressing mycobacterial antigen 85A (MVA85A). Given the widespread use of the current TB vaccine, BCG, many of the new TB vaccines are being tested for their ability to...

    journal_title:Expert review of vaccines

    pub_type: 评论,杂志文章

    doi:10.1586/erv.11.144

    authors: McMurray DN

    更新日期:2011-12-01 00:00:00

  • An overview of in silico vaccine design against different pathogens and cancer.

    abstract:INTRODUCTION:Due to overcome the hardness of the vaccine design, computational vaccinology is emerging widely. Prediction of T cell and B cell epitopes, antigen processing analysis, antigenicity analysis, population coverage, conservancy analysis, allergenicity assessment, toxicity prediction, and protein-peptide docki...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1080/14760584.2020.1794832

    authors: Kardani K,Bolhassani A,Namvar A

    更新日期:2020-08-01 00:00:00

  • Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges.

    abstract::The need for an affordable, safe and effective HIV vaccine has never been greater. As the immunogenicity of all the vaccine vectors being evaluated currently in human populations is limited, novel vaccine strategies are needed to stimulate the innate immune system, to generate high levels of neutralizing antibodies an...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.5.6.827

    authors: Joseph J,Saubi N,Pezzat E,Gatell JM

    更新日期:2006-12-01 00:00:00

  • Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.

    abstract::Active immunotherapy aimed at the stimulation of tumor-specific T cells has established itself within the clinic as a therapeutic option to treat cancer. One strategy is the use of so-called peptides that mimic genuine T-cell epitopes as vaccines to activate tumor-specific T cells. In various clinical trials, differen...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2014.862499

    authors: Talebian Yazdi M,Keene KR,Hiemstra PS,van der Burg SH

    更新日期:2014-01-01 00:00:00

  • Fluzone® High-Dose Influenza Vaccine.

    abstract:INTRODUCTION:Fluzone® High-Dose (IIV3-HD) is a trivalent, inactivated, split-virus influenza vaccine indicated for use in older adults (≥65 years of age). It contains 60 µg hemagglutinin of each influenza strain, which is four times the hemagglutinin content of standard-dose influenza vaccines, including Fluzone (IIV3-...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2016.1254044

    authors: Robertson CA,DiazGranados CA,Decker MD,Chit A,Mercer M,Greenberg DP

    更新日期:2016-12-01 00:00:00

  • Vaccine profile of herpes zoster (HZ/su) subunit vaccine.

    abstract:INTRODUCTION:Herpes zoster (HZ) causes an often severe and painful rash in older people and may be complicated by prolonged pain (postherpetic neuralgia; PHN) and by dissemination in immune-compromised patients. HZ results from reactivation of latent varicella-zoster virus (VZV) infection, often associated with age-rel...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1080/14760584.2017.1329012

    authors: Cunningham AL,Heineman T

    更新日期:2017-07-01 00:00:00

  • Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.

    abstract::The management of advanced prostate cancer, specifically metastatic castrate-resistant prostate cancer (mCRPC), remains a therapeutic challenge. Sipuleucel-T (Provenge; APC8015) was approved by the FDA in 2010 for the treatment of asymptomatic or minimally symptomatic mCRPC patients, and it remains the only FDA-approv...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.2015.1099437

    authors: Wei XX,Fong L,Small EJ

    更新日期:2015-01-01 00:00:00

  • Intradermal naked plasmid DNA immunization: mechanisms of action.

    abstract::Plasmid DNA is a promising vaccine modality that is regularly examined in prime-boost immunization regimens. Recent advances in skin immunity increased our understanding of the sophisticated cutaneous immune network, which revived scientific interest in delivering vaccines to the skin. Intradermal administration of pl...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.11.66

    authors: Elnekave M,Furmanov K,Hovav AH

    更新日期:2011-08-01 00:00:00

  • The value of HIV protective epitope research for informed vaccine design against diverse viral pathogens.

    abstract::The success of vaccine regimens against viral pathogens hinges on the elicitation of protective responses. Hypervariable pathogens such as HIV avoid neutralization by masking protective epitopes with more immunogenic decoys. The identification of protective, conserved epitopes is crucial for future vaccine candidate d...

    journal_title:Expert review of vaccines

    pub_type: 社论

    doi:10.1586/14760584.2014.928597

    authors: Kramer VG,Byrareddy SN

    更新日期:2014-08-01 00:00:00

  • Changing from whole-cell to acellular pertussis vaccines would trade superior tolerability for inferior protection.

    abstract::Notifications of infant deaths, assumed to be related to the introduction of new pentavalent DTwP-Hib-HBV childhood vaccines, caused, during 2008-2010 in few Asian countries, temporary interruptions of the respective vaccination programs. The sudden appearance of fatal cases was due to increased awareness/publicity an...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章

    doi:10.1586/14760584.2015.1059759

    authors: Herzog C

    更新日期:2015-01-01 00:00:00

  • Developmental immunology and vaccines: cellular immune development and future vaccine strategies.

    abstract::This section deals with how new knowledge of the development of cellular immunity in the neonatal period informs vaccine development and reviews the immune responses of the most vulnerable group of newborns, those born prematurely, to vaccines. It describes how the development of future vaccine strategies relies on a ...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.3.4.339

    authors: Prescott S

    更新日期:2004-08-01 00:00:00

  • Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.

    abstract::Serogroup B Neisseria meningitidis is the leading cause of meningococcal disease in developed countries. There is currently no vaccine offering wide-ranging protection. Development of a serogroup B polysaccharide-based vaccine has been hindered by potential risks of autoantibodies that cross-react with glycosylated ho...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/erv.10.116

    authors: Bai X,Borrow R

    更新日期:2010-10-01 00:00:00

  • Current challenges in the development of vaccines for pneumonic plague.

    abstract::Inhalation of Yersinia pestis bacilli causes pneumonic plague, a rapidly progressing and exceptionally virulent disease. Extensively antibiotic-resistant Y. pestis strains exist and we currently lack a safe and effective pneumonic plague vaccine. These facts raise concern that Y. pestis may be exploited as a bioweapon...

    journal_title:Expert review of vaccines

    pub_type: 杂志文章,评审

    doi:10.1586/14760584.7.2.209

    authors: Smiley ST

    更新日期:2008-03-01 00:00:00